All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
1 warning event since 2017; the latest 2018-03-13.
From the record
Axogen, Inc.'s filings since 2017 show 1 warning event: an auditor change (8-K item 4.01, the latest 2018-03-13) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
+20.8% a year over 10 filed years; profitable in 0 of 10.
From the record
Axogen, Inc.'s 10 filed years say what it did: revenue went from $41 million in fiscal 2016 to $225 million in fiscal 2025, up 20.8% a year; it rose in 9 of 9 years; it never fell from a peak; net income was positive in 0 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 7.2/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Axogen, Inc.'s shareholder treatment is put at 7.2 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 28% of 27 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
ROE -12%: lost 12¢ per shareholder dollar. Leverage 42%: owes 42¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Axogen, Inc. lost about 12 cents for every dollar of shareholders' money, and gross profitability: its products earned about 75 cents per dollar of everything the company owns. Leverage: it owed about 42 cents per dollar of assets, and net share issuance: its share count grew 4.1% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
top 28% of 24 in its family; net margin -7%.
From the record
Axogen, Inc.'s standing among 24 graded names in its industry family: revenue of $225 million in fiscal 2025 ranks in the top 27% by size; a net margin of -7% ranks in the top 31%; revenue growth of 17.6% a year over the last 3 filed years ranks in the top 26% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 46% of 19 in its family for leadership; chief executive since 2024.
From the record
Axogen, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Dale, Michael D (Chief Executive Officer, as filed), filing under that title since 2024-08-09, 2.3 years (bottom 47% of its family); the 13 officers and directors filing in the last fifteen months have been on the record a median of 3.9 years (top 50%); 9 officer or director changes were reported on Form 8-K since 2023-11-13, against the 13 people in charge now (bottom 42%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 48% of 23 in its family for room to expand.
From the record
Axogen, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $36 million against debt of $48 million leaves -5.8% of its assets as net cash, bottom 17% of its family; cash from operations less capital spending is -1.3% of revenue (top 37%); a gross margin of 74.3% (top 28%); research spending of 14.6% of revenue (top 43%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 44% of 25 in its family for growth drivers.
From the record
Axogen, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew 17.6% a year over the last three filed years against 20.8% over all 10, slowing (bottom 41% of its family); the newest year grew 20.2% (top 41%); research spending grew 8.7% a year (top 38%); capital spending grew -42.9% a year (bottom 15%) (its annual reports). Axogen, Inc. tags no split of its revenue by line in the annual report on file, so growth by line cannot be read here; research and capital spending are on the trend.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 41% of 20 in its family for expectations against reality.
From the record
Axogen, Inc.'s newest year against its own record: revenue of $225 million in fiscal 2025 came in 3.4% above the $218 million its prior three years' pace pointed to (top 45% of its family); net income of $16 million against a prior three-year average of $20 million (top 30%); a net margin of -7% against -13.3% before (top 47%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made